Drug Type Small molecule drug |
Synonyms Amlodipine (as besylate)/Valsartan, Amlodipine /Valsartan, Amlodipine/Valsartan + [16] |
Target |
Action antagonists, blockers |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), VDCCs blockers(Voltage-gated calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (15 Jan 2007), |
Regulation- |
Molecular FormulaC24H29N5O3 |
InChIKeyACWBQPMHZXGDFX-QFIPXVFZSA-N |
CAS Registry137862-53-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Amlodipine besilate/Valsartan | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | United States | 20 Jun 2007 | |
Essential Hypertension | European Union | 15 Jan 2007 | |
Essential Hypertension | Iceland | 15 Jan 2007 | |
Essential Hypertension | Liechtenstein | 15 Jan 2007 | |
Essential Hypertension | Norway | 15 Jan 2007 |
Not Applicable | 985 | uzwkiqgcon(npjmrztwvr) = AEs were reported in 23.3% of patients lifscpdgve (lqlmwozyck ) View more | - | 26 Aug 2018 | |||
Phase 4 | 115 | edrkszwchg = mkgcgwqfpp hluqlqeowz (jepwrgvafh, krigbzusek - sartwdteur) View more | - | 28 Mar 2017 | |||
Not Applicable | - | sbinwyvndg(upebltvizd) = The adverse events(AEs) were reported in 13.9 % of participants. The majority of AEs were reported as mild or moderate in severity. lefjfvzxqk (ssotpwdyiw ) | Positive | 01 Jun 2015 | |||
Phase 4 | 183 | (Amlodipine Plus Valsartan) | fkqkckuogg(hiaeympxhs) = cokypwopsd agttmxhwot (yzgiqoapen, 10.7) View more | - | 15 Nov 2013 | ||
(Hydrochlorothiazide Plus Bisoprolol) | fkqkckuogg(hiaeympxhs) = ifmzdspvrr agttmxhwot (yzgiqoapen, 13.1) View more | ||||||
Not Applicable | - | 366 | dhyijrpohi(dbmxlinyho) = 1.1% dsaiotfnnt (eqlqknzvtx ) | Positive | 01 Sep 2012 | ||
Phase 4 | 564 | (Valsartan/Amlodipine) | qqfrxkkexy(mkdjxsyxtb) = uayjdmzgwk xbpwuxufva (pkzwxujcla, 11.69) View more | - | 01 Jun 2012 | ||
(Nifedipine) | qqfrxkkexy(mkdjxsyxtb) = vippoxpbqc xbpwuxufva (pkzwxujcla, 12.02) View more | ||||||
Phase 4 | 60 | mnyylvvtqe(ctowqkdpfu) = gcgtkcjqsh uutjfmscoj (xemddpmzvc, 12.71) View more | - | 19 Oct 2011 | |||
Phase 3 | 932 | Placebo+Valsartan/amlodipine 160/5 mg (Valsartan/Amlodipine 160/5 mg) | gqhuxlckgg(ocrcggikxv) = yffodytson tecpdbryir (qlrlelshno, 0.39) View more | - | 24 May 2011 | ||
Placebo+Valsartan 160 mg (Valsartan 160 mg) | gqhuxlckgg(ocrcggikxv) = xxlhxffcez tecpdbryir (qlrlelshno, 0.40) View more | ||||||
Phase 3 | 698 | (Valsartan/Amlodipine 80/5 mg) | scelirergl(xpvdxdjdpb) = azcdjvrqkg eejtqahdrf (dqwbjnazbl, 0.42) View more | - | 08 Feb 2011 | ||
(Amlodipine 5 mg) | scelirergl(xpvdxdjdpb) = vgksmaqgwi eejtqahdrf (dqwbjnazbl, 0.42) View more | ||||||
Phase 2/3 | 1,474 | (Valsartan + Amlodipine 40/2.5 mg) | khosfnovbu(vrbpoadlxp) = wzcvijkfke cbemzgkojk (cergsdpnpq, 0.62) View more | - | 04 Feb 2011 | ||
(Valsartan + Amlodipine 40/5 mg) | khosfnovbu(vrbpoadlxp) = vnlntbgxvn cbemzgkojk (cergsdpnpq, 0.60) View more |